6 September, 2021

Success during the ESOT Congress in Milan

The DTI Foundation’s representatives had a great pleasure of participating in the Congress of the European Society for Organ Transplantation (ESOT), which took place from August 29 to September 1 in Milan, Italy. It was the 20th edition of the event, which covered the full spectrum of organ transplantation activities. The Congress was an invaluable opportunity to meet and exchange knowledge and best practices with professionals who are working in the field and are involved in healthcareand research with an affiliation in transplantation, such as transplant surgeons, physicians, coordinators, nurses and dietitians, general surgeons and clinicians with an interest in transplantation, transplant scientist, nutrition and rehabilitation specialists, and transplant pharmacists.

During the Congress, the President of DTI Foundation, Martí Manyalich, has received the ESOT Honorary Membership in recognition of his persistent efforts in the field of organ donation and transplantation. His professionalism and the perseverance shown throughout his career confirm the well-deserved award.

Moreover, the DTI’s Director of International Cooperation & Development, Chloë Ballesté, has been elected as a Councillor in the ESOT Council Elections. Chloë Ballesté was also a speaker in the session called “Yes we can! How to start a DCD programme”, where she explored the ins and outs of donation after circulatory death programs and explained how to start one.

DTI’s Tissues and Cells Unit Director, Estephan Arredondo, was a speaker during a panel titled “Predictive models and tools in transplantation: Looking into the crystal ball”. He shared his expertise about I-DTI, a second opinion platform between healthcare professionals related to organ donation and transplantation. The ESOT 2021 has provided its attendees with the most recent information on emerging trends in organ transplantation, and the latest information to understand all the changes and updates, such as the role of infectious diseases in posttransplant, the advances in chimeric antigen receptor (CAR) T-cell immunotherapy in hematologic malignancies and the management of therapy-relaxed toxicities.